dacarbazine has been researched along with mannitol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boockvar, JA; Burkhardt, JK; Riina, HA; Shin, BJ | 1 |
| Choi, C; Kim, HM; Kim, HT; Kim, NK; Kim, OJ; Oh, SH; Park, J; Shon, J | 1 |
| Alter, RA; Boockvar, JA; Chakraborty, S; Demopoulos, A; Filippi, CG; Fralin, S; Kulason, KO; Langer, DJ; Ortiz, R; Pramanik, B; Ray, A; Schneider, JR; Tan, K; Wong, T | 1 |
1 review(s) available for dacarbazine and mannitol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for dacarbazine and mannitol
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Blood-Brain Barrier; Brain Neoplasms; Cetuximab; Dacarbazine; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Male; Mannitol; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; Treatment Outcome | 2012 |
Additional increased effects of mannitol-temozolomide combined treatment on blood-brain barrier permeability.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Capillary Permeability; Cell Line; Dacarbazine; Drug Synergism; Humans; Male; Mannitol; Rats; Rats, Sprague-Dawley; Temozolomide; Tight Junction Proteins | 2018 |
Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Topics: Angiography, Digital Subtraction; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Blood-Brain Barrier; Brain Neoplasms; Cerebral Angiography; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Craniotomy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioblastoma; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Mannitol; Middle Aged; Temozolomide; Treatment Outcome | 2018 |